Molecular and cellular signatures of human vaccine adjuvants. - Wikidata - wikimedia - TriplyDB

Molecular and cellular signatures of human vaccine adjuvants.

Molecular and cellular signatures of human vaccine adjuvants.

http://www.wikidata.org/entity/Q30370898

about

Vaccine adjuvants: mode of action Immune mechanisms of protection: can adjuvants rise to the challenge?T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection Adjuvants: Classification, Modus Operandi, and Licensing Hepatitis B virus therapy: What's the future holding for us?Beyond empiricism: informing vaccine development through innate immunity research Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults Immune response to vaccine adjuvants during the first year of life Local innate immune responses in the vaccine adjuvant-injected muscle Oxidation by neutrophils-derived HOCl increases immunogenicity of proteins by converting them into ligands of several endocytic receptors involved in antigen uptake by dendritic cells and macrophages Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats Extracellular matrix from porcine small intestinal submucosa (SIS) as immune adjuvants Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice The avian influenza vaccine Emerflu. Why did it fail?Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Influenza vaccines: a moving interdisciplinary field.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Emulsion-based adjuvants for influenza vaccines.MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine.An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.New adjuvanted vaccines in pregnancy: what is known about their safety?Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial Inactivated influenza vaccines: recent progress and implications for the elderly.MF59 adjuvant: the best insurance against influenza strain diversity.De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients.The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients.Immunobiology of influenza vaccines Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.Not Just a Sum? Identifying Different Types of Interplay between Constituents in Combined Interventions Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites Enzymatic stability and immunoregulatory efficacy of a synthetic indolicidin analogue with regular enantiomeric sequence.The TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology Comparative pathogenesis and systems biology for biodefense virus vaccine development.Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine.

P2860

Q21131210-9735F555-FF31-4B6F-818D-658436CB271D Q21245319-BECDBD4C-5EA4-4005-A61C-BF3E10A4B163 Q24645758-973172F5-3994-4EC8-9AE1-4E294387BCCE Q26747586-1C12E073-946D-4A54-8510-08C0D512832C Q26774198-706D16BE-48B5-4EEE-924B-FA30B1155E12 Q26824573-7F822E60-34BE-4FF9-B466-88C76AE0DD9E Q27009478-829CF26F-1D9B-4C9E-8FF2-099158C9F632 Q27016633-3A1CD21B-928F-40FF-A064-9EB134BC0119 Q28079872-11B10103-C76F-43AA-B0AF-EF5AF642963C Q28391399-2A136A9E-D0D2-4444-86C3-B3AF40E9B341 Q28730561-676FCEAE-7B61-4EE5-8ECF-7B4BDDC1F06C Q28730610-B26C3200-5DA3-4FA2-ABA0-CE487A521B49 Q28743077-720307A5-D5CB-4BBC-B449-1D37930942FC Q28749625-BDFB1C10-9415-4065-A2D1-99D8FFFE4E11 Q30203302-524E427E-32B4-4A95-B5A4-A45B388ECC88 Q30204573-55DABC08-41EC-4E7E-BADE-7155D806B0BA Q30367695-C49BE65B-4CCC-466B-AAB2-B7469E824124 Q30371303-65E8CF8A-F8FD-4D4A-B2F1-CD96075F883C Q30375985-18EFA78C-00F9-4076-ABE0-A0D6960A87D9 Q30377215-D3C43996-04E6-4F48-B3E8-9C78068DEC57 Q30383740-95ADA674-32DC-4770-B92B-8135A4E265FB Q30390234-72676D8B-0E0D-452D-9502-B5AD35F8F466 Q30394545-8B9365C1-84B7-46E6-BCBE-0323E8513F71 Q30396657-A3878F08-27D4-4AD5-AD0C-831A06D73980 Q30397652-3BA6B986-8A34-4420-AB43-1C891C6D0319 Q30399057-2D54005C-7B5D-4EF2-B21B-7E900A33C8FE Q30402018-1356DB3D-18D6-47B3-B1D6-B117A8E735A0 Q30403833-F298EA4F-3613-4F35-BBA0-E259B8C2B65F Q30417273-3B81E325-D2B7-4ADD-99F6-83527FD088FA Q30421428-B4B3FC01-3D40-4A17-8157-A6F1D41E4DB8 Q30426771-F68F083D-EE91-4A55-BDCF-243A15C55F1C Q30436915-0593B814-5314-48CF-B117-FA53CE308C37 Q30650188-DC6D6B2B-D954-4267-AA8D-AF889B1C0063 Q33614461-F0B254C5-8F59-497F-ADCD-C48B6392A415 Q33635680-35173425-788D-40A3-BBF5-F308870A5B35 Q33673210-B005DEB4-AD9D-40F2-BCC0-3B0E0C90C75E Q33809953-12E4D7EE-59D2-4B3A-BB54-9224091A8183 Q33930469-70F8FF7F-AECC-48CA-AD28-C9080B5C5160 Q33959989-5DD21C94-940F-430E-A93E-4B72E9B7B9E7 Q34086657-C3032101-C970-4EC7-B312-AAC8C0CC0EA4

P2860

Molecular and cellular signatures of human vaccine adjuvants.

http://www.wikidata.org/entity/Q30370898

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Molecular and cellular signatures of human vaccine adjuvants.

@ast

Molecular and cellular signatures of human vaccine adjuvants.

@en

type

label

Molecular and cellular signatures of human vaccine adjuvants.

@ast

Molecular and cellular signatures of human vaccine adjuvants.

@en

prefLabel

Molecular and cellular signatures of human vaccine adjuvants.

@ast

Molecular and cellular signatures of human vaccine adjuvants.

@en

P1433

Q30370898-11679FEC-10FA-49E2-8339-2ABE1543D7D2

P1476

Q30370898-1693C508-C1AB-49E4-9729-3B57B4458B45

P2093

Q30370898-21FCF23D-56FC-4E3F-93D9-DA992FE2383C

Q30370898-3879039B-A830-4D22-A660-844F08CD6644

Q30370898-7CF81556-715C-4DE6-B5F9-890D845848A9

Q30370898-8E485D6F-44A4-4768-A418-478865BAE79B

Q30370898-B8CCD000-911C-474C-B1B0-F3BEE08D4537

Q30370898-BCB18A4B-618D-41E5-869D-246FBD2F4ABF

Q30370898-CDF5E70F-8F17-43C3-AA0B-5F657B22D253

Q30370898-E650A031-DB1C-492D-83E3-E5A8D766D4E8

Q30370898-F948CDDD-39F1-46C3-8ADF-E6F7EC49E293

P2860

Q30370898-0BCEB429-92FD-4ADC-B496-5A0D901F8C77

Q30370898-1EA24DF2-A29A-4A40-8A76-6E01A82E26CE

Q30370898-218CF173-2371-4716-912C-B1746DBC4BD2

Q30370898-24478678-AD65-402E-967D-ADB46DF32EF3

Q30370898-2F5878A5-4231-49AB-8AAB-D29AC195AC0F

Q30370898-312981BA-01B2-4898-812B-57148C84B2AA

Q30370898-3ED6834A-A7EF-4A03-AE7F-B7466EA5B2EA

Q30370898-46728B74-8EFD-4911-B588-30D4F6CDC53F

Q30370898-4A1765E4-43B3-4ACD-A038-704310BB2B4F

Q30370898-5DA1A1B7-8459-4DD3-B452-8E267977AC64

P304

Q30370898-2E1EE997-2463-4EB0-B41B-D6333728AAD4

P31

Q30370898-4EA60C68-5118-4830-9E70-D94A7800468D

P356

Q30370898-F3A4A005-A752-4060-835E-1B726303A269

P407

Q30370898-268AAE7D-DC81-49E7-8727-F3F95E1D973D

P433

Q30370898-4A36BD58-D974-48C2-9D8F-3F37DF40F907

P478

Q30370898-86025C86-360B-41B1-97DC-C8DA78591E88

P577

Q30370898-F2978D98-B5D0-40AA-8DB4-B2726270AA10

P5875

Q30370898-A05F6B3F-7D28-4638-B5D0-C65DC59B98C9

P698

Q30370898-B021DACA-0D07-443F-9C0B-6E0600C95ED6

P932

Q30370898-D3D7178F-2679-41A7-BD6A-596BBD371058

P356

PNAS.0804699105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Molecular and cellular signatures of human vaccine adjuvants.

@en

P2093

A Muzzi

http://www.w3.org/2001/XMLSchema#string

C Iavarone

http://www.w3.org/2001/XMLSchema#string

D O'Hagan

http://www.w3.org/2001/XMLSchema#string

E De Gregorio

http://www.w3.org/2001/XMLSchema#string

E Monaci

http://www.w3.org/2001/XMLSchema#string

E Tritto

http://www.w3.org/2001/XMLSchema#string

F Bagnoli

http://www.w3.org/2001/XMLSchema#string

F Mosca

http://www.w3.org/2001/XMLSchema#string

R Rappuoli

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data.

TM4: a free, open-source system for microarray data management and analysis

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response.

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.

P304

10501-10506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0804699105

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51423982

http://www.w3.org/2001/XMLSchema#string

P698

18650390

http://www.w3.org/2001/XMLSchema#string

P932

2483233

http://www.w3.org/2001/XMLSchema#string